简体中文

Professionals

Wu LiPartner

Tel:
+86 10 8567 5988
Fax:
+86 10 8567 5999
Email:
wuli@anjielaw.com
Expertise:
Patent/Trademark Prosecution and Litigation; IP Strategy & Portfolio Management; Consultations on IP laws
Information
     
    Working Experience

    Partner, AnJie Law Firm

    Managing Partner, F&S Intellectual Property Ltd. 

    IP Counsel, AstraZeneca

    Associate, Goodwin Procter LLP., Boston

    Education

    Columbia Law School, J.D., 2007

    Columbia University, Ph.D. in Neuroscience, 2004

    Chinese Academy of Sciences, M.S. in Neuroscience, 1998

    Nanjing University, B.S.,1994

    Affiliations

    Member of All China Lawyers Association

    Member of ALL-China Patent Agents Association

    Committee Member of Beijing Patent Agents Association

    Committee Member of Chinese Intellectual Property Law Association

    Languages

    Chinese

    English


Work Highlights
Practice Description

Dr. Li Wu is an attorney at law and patent attorney qualified to practice in both China and the United States.  He provides services in all aspects of intellectual property law.  On the one hand, he focuses on providing full spectrum of patent services including prosecution, re-examination, invalidation, and litigation, especially in the fields of biotechnology, pharmaceutical, chemical engineering and medical device.  On the other hand, he also advises clients on matters in relation to trademark, copyright, trade secret, unfair competition and other IP related fields.

Prior to joining Anjie law firm, Dr. Wu had served in leading firms in both China and the United States.  In addition, he also had experience in serving as in-house counsel for a multinational pharmaceutical company in China. 

Before starting his legal career, Dr. Wu had worked as a scientist in the field of neuroscience for more than 10 years, and his work on the regulation of calcium channels has been published in the world famous scientific magazine Nature (Vol. 419:947-952).

Representative Matters

Represented AstraZeneca in defending one of its core pharmaceutical compound patent before the courts and successfully overturned the invalidation decision made by the Patent Re-examination Board; 

Represented Japanese company Nichia Corporation in a series of patent litigations against a Taiwan company Everlight Electronic before the Beijing IP Court and the Patent Re-examination Board, which are part of a global patent war between these two LED giants in the world;

Represented a leading auto parts company in a patent litigation concerning a cylinder liner patent before the Beijing IP court and the Patent Re-examination Board and won a completed victory for the client;

Represented Sinopec in a series of trade secret and patent disputes that claimed damages over one billion RMB in total and successfully helped the client achieve a settlement;

Represented a Japanese pharmaceutical company in patent infringement matter concerning a pharmaceutical process patent, the case went through trial and appeal and finally to retrial at the Supreme People’s Court and involved a damage award over RMB 5,000,000;

Represents a US communication company in patent invalidation matter concerning a 4G technology patent and won a completed victory for the to keep all patent claims valid;

Represented a Chinese public company in a 337 investigation before the ITC concerning CoQ10 and its usage. 

Represent or represented high tech start-ups, public companies, multinational giants, as well as research institutions, such as Sinopec, Toyota, NEC, Yazaki, Novartis, Nihon Kohden, Align Technology, Nichia, Michigan University, UCSF, UCLA, Chinese Academy of Science, Qinghua University, Nanjing University, etc. in patent prosecution related matters concerning chemical engineering, autos, electrical engineering, pharmaceuticals, life sciences and medical devices, and successfully obtained and protected hundreds of patents in these fields;

Representative Publications

“Data supplementation for chemical and biotech patents in China”,  Chinese Business Law Journal, June 2018

"China to establish its own drug patent linkage", Chinese Business Law Journal, November 2017

"Coming to terms with the US introduction of DTSA", Chinese Business Law Journal, October, 2016

"Particularities of China's Biotechnology Patent Protection Regime", Chinese Business Law Journal, October, 2015

"Fourth amendment to Patent Law aims to increase damages and more", Chinese Business Law Journal, May, 2015

"SIPO Clarifies Its Sufficient Disclosure Requirement", Managing IP, February 2014

"Foreign enterprises should study China’s utility model patent regime", Chinese Business Law Journal, December, 2013

"DNA patentability in China", Symposium of the SIPO/US Bar Liaison Council with China's State Intellectual Property Office (SIPO) and the All China Patent Attorney Association (ACPAA), June 3, 2013 at Cardozo School of Law, New York, USA.
Beijing Office

19/F, Tower D1, Liangmaqiao Diplomatic Office Building, No. 19 Dongfangdonglu, Chaoyang District, Beijing 100600

Tel:+86 10 8567 5988

Fax:+86 10 8567 5999

Shanghai Office

28/F, K.Wah Center,
No. 1010 Huaihai Road (M), Shanghai 200031

 

Tel:+86 21 2422 4888

Fax:+86 21 2422 4800

Shenzhen Office

38/F, Tower 3, Kerry Plaza,
No. 1-1 Zhongxinsi Road, Futian District, Shenzhen 518041

Tel:+86 755 8285 0609

Fax:+86 755 8285 0605

Follow us:

WeChat sweep
© 2016 - Copyright ANJIE - All Rights Reserved Designed by GreatMo